Suppliers and packagers for suprane

suprane

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118	NDA	Henry Schein, Inc.	0404-9961-25	1 BOTTLE in 1 BAG (0404-9961-25) / 240 mL in 1 BOTTLE	2022-01-12
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118	NDA	Baxter Healthcare Corporation	10019-641-34	6 BOTTLE in 1 CARTON (10019-641-34) / 240 mL in 1 BOTTLE (10019-641-64)	1992-09-18
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118	NDA	Baxter Healthcare Corporation	10019-644-34	6 BOTTLE in 1 CARTON (10019-644-34) / 240 mL in 1 BOTTLE (10019-644-64)	1992-09-18
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118	NDA	Baxter Healthcare Corporation	10019-646-34	6 BOTTLE in 1 CARTON (10019-646-34) / 240 mL in 1 BOTTLE (10019-646-64)	1992-09-18

Suppliers for the Pharmaceutical Drug: Suprane

Last updated: July 29, 2025

Introduction

Suprane, known generically as desflurane, is an inhalational anesthetic used to induce and maintain general anesthesia during surgical procedures. Its rapid onset and offset make it a preferred choice among anesthesiologists, particularly in outpatient surgeries. The pharmaceutical supply landscape for desflurane is complex, involving multiple manufacturers, suppliers, and distribution networks globally. This article explores the key suppliers for Suprane, analyzing the competitive environment, manufacturing strategies, and implications for stakeholders.

Overview of Suprane and Its Market

Introduced by Baxter International in the 1990s, Suprane rapidly gained market share due to its unique pharmacokinetic profile. While other anesthetics like sevoflurane and isoflurane are also prevalent, desflurane's fast recovery profile sustains its demand in specialized medical settings. The global desflurane market is valued in the hundreds of millions of dollars, with major players including Baxter, Maruishi Pharmaceutical, Maruishi, and regional Asian manufacturers.

Primary Manufacturers and Suppliers of Suprane

Baxter International Inc.

Baxter is the original patent holder and sole supplier of Suprane in multiple markets, notably North America and parts of Europe. The company has a vertically integrated manufacturing process, controlling the entire supply chain from raw material sourcing to formulation and packaging. Baxter's reputation for quality and reliability maintains its dominant position, although production capacity and patent expirations influence market dynamics.

Maruishi Pharmaceutical Co., Ltd.

Maruishi is a leading Japanese pharmaceutical firm manufacturing desflurane under its own brand and as an authorized supplier for Baxter in certain Asian markets. The company has established a robust regional distribution network with compliance to stringent Japanese and regional pharmaceutical standards, making it a reliable local source.

Mundipharma International Limited

Mundipharma supplies desflurane in select European markets, operating through licensing agreements and distribution partnerships. Their focus on regional regulatory compliance and tailored marketing provides them with footholds in competitive markets.

Regional and Generic Manufacturers

Despite Baxter's dominance, several regional manufacturers have entered the market through licensing agreements or by producing generic versions following patent expirations. These players often serve emerging markets with cost-competitive products. Examples include:

• Wang Wei Pharmaceuticals (China)
• Jiangsu Hengrui Medicine (China)
• Asian Med Innovations (India)

Note: These companies typically produce desflurane formulations compliant with regional regulatory standards, although their products may differ in packaging and added excipients.

Supply Chain and Distribution Networks

The supply of Suprane relies heavily on regional distribution channels, including hospitals, clinics, and anesthesia providers. Baxter and other primary manufacturers distribute through authorized pharmaceutical distributors, Valeant Specialty Pharmaceuticals, and regional agents. Geographic considerations influence supplier selection, with European, American, and Asian markets often contracting with localized distributors.

Distribution often involves the shipment of compressed gas cylinders, vaporizers, and ampoules of desflurane. The stability and safety of these supplies are strictly regulated by agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and regional counterparts.

Regulatory Considerations and Their Impact on Suppliers

Manufacturers must adhere to stringent Good Manufacturing Practices (GMP), obtaining approvals from regional regulators. Patent protections and exclusivity rights affect the entry of generic suppliers. As patents expire, an increased number of generic producers are expected to enter the market, potentially reducing costs and broadening supplier options.

For example, Baxter's patent exclusivity in certain jurisdictions limits competition; however, legal battles and patent cliffs periodically usher in generic alternatives, reshaping the supplier landscape.

Emerging Trends: Localization and Diversification

In recent years, manufacturers have adopted strategies such as regional manufacturing hubs and joint ventures to mitigate supply chain risks. This diversification enhances resilience against geopolitical disruptions, supply bottlenecks, and regulatory delays.

Furthermore, sustainable manufacturing practices and production certifications (ISO, GMP) are increasingly critical differentiators for suppliers, influencing hospital procurement decisions and insurance reimbursements.

Challenges Facing Suppliers

• Supply Chain Disruptions: The COVID-19 pandemic underscored vulnerabilities, impeding raw material procurement and distribution logistics.
• Regulatory Barriers: Variable approval processes across countries delay market entry for new suppliers.
• Patent Expirations: Open the market to generics, increasing competition but reducing profit margins for original manufacturers.
• Environmental Regulations: Stringent controls on greenhouse gases influence manufacturing emissions and waste management for inhalational agents.

Opportunities and Outlook

The increasing global demand for anesthesia agents, driven by rising surgical procedures and expanding healthcare infrastructure, presents opportunities for current and emerging suppliers. Additionally, technological advancements in vaporizer safety and environmentally friendly anesthetic formulations could stimulate new supplier participation.

Baxter continues to innovate, seeking to improve product delivery systems and reduce environmental impact, thus maintaining its dominance. Meanwhile, regional manufacturers aim to capture local markets by leveraging cost advantages and compliance with regional standards.

Conclusion

The supply landscape for Suprane (desflurane) remains predominantly characterized by Baxter International as the primary global supplier, with regional and generic manufacturers expanding their roles, especially post-patent expiration. The market's future will depend on regulatory developments, innovation in medical gases, supply chain resilience, and environmental considerations.

Stakeholders should monitor patent timelines, regional manufacturing policies, and evolving safety standards to navigate and capitalize on the supplier ecosystem effectively.

---

Key Takeaways

• Baxter International maintains global dominance as the primary supplier of Suprane (desflurane), leveraging extensive manufacturing and distribution infrastructure.
• Regional manufacturers, particularly in Asia and Europe, supply desflurane through licensing agreements, with an increased presence following patent expirations.
• Supply chain stability and regulatory compliance remain critical factors influencing supplier reliability and market access.
• Innovations in environmentally sustainable anesthetic delivery and manufacturing processes may redefine supplier strategies.
• The evolving landscape post-patent expiration presents opportunities for generic manufacturers but also heightens competition and market dispensability risks for original patent holders.

---

FAQs

1. Who are the main global suppliers of Suprane (desflurane)?
Baxter International remains the primary and most prominent global supplier, with regional manufacturers such as Maruishi Pharmaceutical and licensed generic producers serving various markets post-patent expiration.

2. Are there alternative sources for desflurane besides Baxter?
Yes. Several regional manufacturers produce generic desflurane, especially in Asia and Europe, following patent expirations. These sources mainly serve local markets and comply with regional regulatory standards.

3. How does patent protection influence the supply landscape of Suprane?
Patent protections limit generic competition during exclusivity periods, maintaining Baxter's market dominance. Once patents expire, numerous generic suppliers can enter, increasing supply options but also market competition.

4. What are the key challenges faced by desflurane suppliers?
Challenges include supply chain disruptions, regulatory hurdles, patent expirations, environmental regulations, and the need for continuous innovation to improve safety and sustainability.

5. What trends could impact future Suprane supply dynamics?
Emerging trends include regional manufacturing strategies, environmentally friendly formulations, digital supply chain innovations, and shifts in healthcare infrastructure globally, all influencing supplier strategies and market stability.